Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) James V. Freeman et al.   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) Amanda R. Harrington et al.   STROKE

Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation

(2013) Doug Coyle et al.   VALUE IN HEALTH

Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

(2012) Soyon Lee et al.   AMERICAN JOURNAL OF CARDIOLOGY

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

(2012) Stefan H. Hohnloser et al.   CIRCULATION

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation

(2012) Joyce H. S. You et al.   PLoS One

Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

(2011) Shimoli V. Shah et al.   CIRCULATION

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission

(2009) Harlan M. Krumholz et al.  

Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?

(2008) Geno J. Merli et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS